Chester County News and Community Website
EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented …
Read More EXTON, PA — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced final topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist.
Read More